blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3497104

EP3497104 - SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  03.09.2021
Database last updated on 25.09.2024
FormerGrant of patent is intended
Status updated on  11.03.2021
FormerExamination is in progress
Status updated on  18.03.2020
FormerRequest for examination was made
Status updated on  17.05.2019
FormerThe international publication has been made
Status updated on  17.02.2018
Formerunknown
Status updated on  01.09.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Teva Pharmaceuticals International GmbH
Schlüsselstrasse 12
8645 Jona / CH
[2021/33]
Former [2019/25]For all designated states
Assia Chemical Industries Ltd.
2 Denmark Street
49517 Petach Tikva / IL
Inventor(s)01 / MITTELMAN, Ariel
13/4 Shimon Hatsadik St.
Elad / IL
02 / FUCHS, Ido
48 Maskin St. Apt. 21
Petah Tikva / IL
03 / SHACHANTOV, Sharona
Shrat Moshe 21/7
Kfar-Saba / IL
04 / RUDIK, Doron
9 Levona St.
Modiin / IL
05 / SELLA-EREZ, Rotem
9/6 Sderot Chen St.
Tel-Aviv / IL
 [2019/25]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2019/25]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date17754571.208.08.2017
[2019/25]
WO2017US45877
Priority number, dateUS201662372553P09.08.2016         Original published format: US 201662372553 P
US201662382479P01.09.2016         Original published format: US 201662382479 P
US201662382977P02.09.2016         Original published format: US 201662382977 P
US201662400358P27.09.2016         Original published format: US 201662400358 P
US201762486554P18.04.2017         Original published format: US 201762486554 P
[2019/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018031535
Date:15.02.2018
Language:EN
[2018/07]
Type: A1 Application with search report 
No.:EP3497104
Date:19.06.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 15.02.2018 takes the place of the publication of the European patent application.
[2019/25]
Type: B1 Patent specification 
No.:EP3497104
Date:06.10.2021
Language:EN
[2021/40]
Search report(s)International search report - published on:EP15.02.2018
ClassificationIPC:C07D471/16, C07C309/30
[2021/09]
CPC:
C07D471/16 (EP,US); C07C309/30 (EP,US); C07D471/06 (EP);
C07B2200/13 (EP,US)
Former IPC [2019/25]C07D471/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/25]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:FESTKÖRPERFORMEN VON LUMATEPERON-DITOSYLATSALZ[2019/25]
English:SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT[2019/25]
French:FORMES SOLIDES DU SEL DITOSYLATE DE LUMATEPERONE[2021/09]
Former [2019/25]FORMES À L'ÉTAT SOLIDE DE SEL DE DITOSYLATE LUMATEPERONE
Entry into regional phase09.02.2019National basic fee paid 
09.02.2019Designation fee(s) paid 
09.02.2019Examination fee paid 
Examination procedure09.02.2019Examination requested  [2019/25]
09.02.2019Date on which the examining division has become responsible
06.11.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
06.11.2019Despatch of communication of loss of particular rights: Claims {1}
17.12.2019Amendment by applicant (claims and/or description)
23.03.2020Despatch of a communication from the examining division (Time limit: M04)
08.07.2020Reply to a communication from the examining division
02.11.2020Despatch of a communication from the examining division (Time limit: M04)
30.11.2020Reply to a communication from the examining division
12.03.2021Communication of intention to grant the patent
19.07.2021Fee for grant paid
19.07.2021Fee for publishing/printing paid
19.07.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21200789.2  / EP4001281
Opposition(s)Opponent(s)01  30.06.2022  06.07.2022  ADMISSIBLE
Intra-Cellular Therapies, Inc.
430 East 29th Street, Suite 900
New York, NY 10016 / US
Opponent's representative
Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
 [2022/34]
Former [2022/32]
Opponent(s)01  30.06.2022  06.07.2022  ADMISSIBLE
Intra-Cellular Therapies, Inc.
430 East 29th Street, Suite 900
New York, NY 10016 / US
Opponent's representative
McNab, Donald C.
Marks & Clerk LLP
40 Torphichen Street
Edinburgh EH3 8JB / GB
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
18.07.2022Invitation to proprietor to file observations on the notice of opposition
28.11.2022Reply of patent proprietor to notice(s) of opposition
25.06.2024Date of oral proceedings
29.07.2024Despatch of minutes of oral proceedings
29.07.2024Date of despatch of rejection of opposition
Request for further processing for:Loss of rights: Claims
23.12.2019Request for further processing filed
23.12.2019Full payment received (date of receipt of payment)
Request granted
20.01.2020Decision despatched
23.12.2019Request for further processing filed
23.12.2019Full payment received (date of receipt of payment)
Request granted
20.01.2020Decision despatched
Fees paidRenewal fee
26.08.2019Renewal fee patent year 03
20.08.2020Renewal fee patent year 04
24.08.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
MT06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
TR06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE08.08.2022
LU08.08.2022
BE31.08.2022
[2024/42]
Former [2024/29]AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
TR06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE08.08.2022
LU08.08.2022
BE31.08.2022
Former [2024/27]AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE08.08.2022
LU08.08.2022
BE31.08.2022
Former [2024/20]AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE08.08.2022
LU08.08.2022
BE31.08.2022
Former [2023/42]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE08.08.2022
LU08.08.2022
BE31.08.2022
Former [2023/33]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE08.08.2022
LU08.08.2022
Former [2023/21]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
LU08.08.2022
Former [2023/16]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/49]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/35]AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/34]AT06.10.2021
EE06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/33]AT06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
RS06.10.2021
SE06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/25]AT06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
RS06.10.2021
SE06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/24]AT06.10.2021
FI06.10.2021
LT06.10.2021
LV06.10.2021
RS06.10.2021
SE06.10.2021
BG06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/22]AT06.10.2021
FI06.10.2021
LT06.10.2021
RS06.10.2021
BG06.01.2022
Former [2022/21]AT06.10.2021
RS06.10.2021
BG06.01.2022
Former [2022/19]BG06.01.2022
Cited inInternational search[YD]WO2009114181  (INTRA CELLULAR THERAPIES INC [US], et al) [YD] 1-22 * abstract * * paragraph [0004] * * pages 3-4 * * paragraphs [0028] - [0029] * * examples 1-5 * * claims 1-20 * * figures 1-10 *;
 [Y]  - CAIRA ED - MONTCHAMP JEAN-LUC, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, (199801), vol. 198, ISSN 0340-1022, pages 163 - 208, XP008166276 [Y] 1-22 * abstract * * bridging paragraph *; pages 165-166 * * pages 177-180, paragraph 3.1. *

DOI:   http://dx.doi.org/10.1007/3-540-69178-2_5
by applicantWO2008112280
 WO2009114181
 US8648077
OppositionWO2009114181
    - MR CAIRA, "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, Berlin, Germany, (19980100), vol. 198, doi:10.1007/3-540-69178-2_5, pages 163 - 208, XP008166276

DOI:   http://dx.doi.org/10.1007/3-540-69178-2_5
    - "United States Pharmacopeia-National Formulary ( USP -NF) official guidelines on performing solubility determinations for drug products and active pharmaceutical ingredients", (14052021), pages 1 - 13
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.